August industrial profits rose 4.2%, the slowest pace of the year, with official surveys due Wednesday and...
The FDA approved Onswik on September 23. The harder question is whether Lilly can manufacture it fast...
The biotech IPO class of 2026 has held up better than expected. ADARx’s first-week fade puts that...
The difference between an earnings-trick buyback and a real valuation call is when management pulls the trigger.
When Tokyo, Paris, and Washington sell off together, this is global, not just Treasuries.
With Q3 closing Wednesday and tax-loss selling hitting consumer names, the real question is which one has...
Wing shortages are slowing the 737 MAX ramp, free cash flow expectations just reset, and Q3 earnings...
With the 10-year near 5% and Goldman calling $4,900, how much gold does a disciplined portfolio actually...
Bessent’s short Busan extension keeps pressure on China until Jan. 10.
Profitability compounding with growth, 126% retention, and fresh targets up to $525 make the post-earnings dip the...